Ascletis initiates participant dosing in Phase II trial of ASC30 for diabetes
Ascletis Pharma has dosed the first participants in a US Phase II trial of ASC30, an oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist, intended for treating type 2 diabetes…